1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Toxoplasmosis Global Clinical Trials Review, H2, 2016

Toxoplasmosis Global Clinical Trials Review, H2, 2016

  • August 2016
  • -
  • Global Data
  • -
  • 38 pages

Toxoplasmosis Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Toxoplasmosis Global Clinical Trials Review, H2, 2016" provides an overview of Toxoplasmosis clinical trials scenario. This report provides top line data relating to the clinical trials on Toxoplasmosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Toxoplasmosis Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2


Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Top Countries Contributing to Clinical Trials in Middle East and Africa 11
Top Countries Contributing to Clinical Trials in Central and South America 12
Clinical Trials by G7 Countries: Proportion of Toxoplasmosis to Infectious Disease Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by E7 Countries: Proportion of Toxoplasmosis to Infectious Disease Clinical Trials 16
Clinical Trials by Phase in E7 Countries 17
Clinical Trials by Phase 18
In Progress Trials by Phase 19
Clinical Trials by Trial Status 20
Clinical Trials by End Point Status 21
Subjects Recruited Over a Period of Time 22
Clinical Trials by Sponsor Type 23
Prominent Sponsors 24
Top Companies Participating in Toxoplasmosis Therapeutics Clinical Trials 25
Prominent Drugs 26
Clinical Trial Profile Snapshots 27
Appendix 35
Abbreviations 35
Definitions 35
Research Methodology 36
Secondary Research 36
About GlobalData 37
Contact Us 37
Disclaimer 37
Source 38

List of Tables
Toxoplasmosis Therapeutics, Global, Clinical Trials by Region, 2016* 5
Toxoplasmosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Toxoplasmosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Toxoplasmosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Toxoplasmosis Therapeutics Clinical Trials, Europe, Top Countries, 2016* 9
Toxoplasmosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Toxoplasmosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 11
Toxoplasmosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 12
Proportion of Toxoplasmosis to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 13
Toxoplasmosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Toxoplasmosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Toxoplasmosis to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 16
Toxoplasmosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Toxoplasmosis Therapeutics, Global, Clinical Trials by Phase, 2016* 18
Toxoplasmosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 19
Toxoplasmosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Toxoplasmosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Toxoplasmosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Toxoplasmosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 23
Toxoplasmosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Toxoplasmosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Toxoplasmosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26

List of Figures
Toxoplasmosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Toxoplasmosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Toxoplasmosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Toxoplasmosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Toxoplasmosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 11
Proportion of Toxoplasmosis to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 13
Toxoplasmosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 14
Toxoplasmosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 15
Proportion of Toxoplasmosis to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 16
Toxoplasmosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 17
Toxoplasmosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 18
Toxoplasmosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 19
Toxoplasmosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 20
Toxoplasmosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 21
Toxoplasmosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 22
Toxoplasmosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 23
Toxoplasmosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 24
Toxoplasmosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 25
Toxoplasmosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 26
GlobalData Methodology 36

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in Africa

  • December 2016
    3 pages
  • Infectious Dise...  

    Therapy  

    Pharmaceutical  

  • Africa  

    World  

View report >

Pathology Statistics in Belgium

  • November 2016
    12 pages
  • Pathology  

    Infectious Dise...  

  • Belgium  

    Europe  

    Syrian Arab Rep...  

View report >

Infectious Disease Statistics

  • November 2016
    12 pages
  • Infectious Dise...  

    Therapy  

  • Niger  

    Kenya  

    Africa  

View report >

Related Market Segments :

Infectious Disease
Therapy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.